Completed PHASE2 INTERVENTIONAL 1-arm NCT01685060

LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib

A Phase II, Multicenter, Single-arm Study of Oral LDK378 in Adult Patients With ALK-activated Non-small Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib

Sponsor: Novartis Pharmaceuticals

Conditions Non-Small Cell Lung Cancer

Interventions LDK378

Updated 8 times since 2017 Last updated: May 25, 2017 Started: Nov 26, 2012 Primary completion: Mar 29, 2016 Completion: Mar 29, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01685060, this PHASE2 trial focuses on Non-Small Cell Lung Cancer and remains completed. Sponsored by Novartis Pharmaceuticals, it has been updated 8 times since 2012, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jul 2017 — Jun 2018 [monthly]

Completed PHASE2
Feb 2017 — Jul 2017 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Nov 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Akashi, Japan , Amsterdam, Netherlands , Atlanta, United States , Aurora, United States , Avellino, Italy , Barcelona, Spain , Boston, United States , Charlotte, United States , Chicago, United States and 40 more locations